Bladder Cancer

Scope & Guideline

Unveiling breakthroughs in bladder cancer management.

Introduction

Explore the comprehensive scope of Bladder Cancer through our detailed guidelines, including its aims and scope. Stay updated with trending and emerging topics, and delve into declining areas to understand shifts in academic interest. Our guidelines also showcase highly cited topics, featuring influential research making a significant impact. Additionally, discover the latest published papers and those with high citation counts, offering a snapshot of current scholarly conversations. Use these guidelines to explore Bladder Cancer in depth and align your research initiatives with current academic trends.
LanguageEnglish
ISSN2352-3727
PublisherIOS PRESS
Support Open AccessYes
CountryNetherlands
TypeJournal
Convergefrom 2015 to 2024
AbbreviationBLADDER CANCER / Bladder Cancer
Frequency4 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
AddressNIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS

Aims and Scopes

The journal 'Bladder Cancer' focuses on advancing the understanding, diagnosis, treatment, and management of bladder cancer through rigorous research and clinical studies. It encompasses a broad range of topics that contribute to the field of urologic oncology.
  1. Clinical Research and Trials:
    The journal emphasizes clinical trials, including novel therapies, surgical techniques, and chemotherapy regimens, to provide evidence-based practices for treating bladder cancer.
  2. Biomarkers and Molecular Studies:
    Research on molecular subtypes, biomarkers, and genetic factors plays a crucial role in understanding bladder cancer pathogenesis and tailoring individualized therapies.
  3. Patient-Centered Approaches:
    The journal highlights studies focusing on patient decision-making, quality of life, and supportive care, recognizing the importance of patient experiences and preferences in treatment outcomes.
  4. Innovative Treatment Modalities:
    Exploration of new treatment strategies, including immunotherapy, targeted therapy, and advanced surgical techniques, reflects the journal's commitment to improving therapeutic options for bladder cancer patients.
  5. Epidemiology and Risk Factors:
    Investigations into the epidemiology, risk factors, and preventive measures related to bladder cancer are integral to understanding disease trends and improving public health initiatives.
The field of bladder cancer research is dynamic, with several emerging themes that have gained traction in recent publications. These trends indicate a shift towards more innovative and patient-focused approaches.
  1. Immunotherapy and Novel Therapeutics:
    A significant increase in studies focusing on immunotherapy, including checkpoint inhibitors and antibody-drug conjugates, highlights a trend towards utilizing the immune system to combat bladder cancer.
  2. Patient Quality of Life and Psychosocial Factors:
    Research exploring the quality of life, psychosocial impacts, and supportive care for bladder cancer patients is on the rise, emphasizing the importance of holistic approaches to treatment.
  3. Integration of Biomarkers in Clinical Practice:
    There is a growing trend towards integrating biomarker studies in clinical settings, enabling personalized medicine approaches that tailor treatments based on individual patient profiles.
  4. Real-World Evidence and Patient-Centric Research:
    Studies utilizing real-world data to assess treatment outcomes and patient experiences are increasingly prominent, reflecting a shift towards understanding the practical implications of treatment in diverse populations.
  5. Management of Non-Muscle Invasive Bladder Cancer (NMIBC):
    An emerging focus on the management strategies for NMIBC, including surveillance protocols and treatment innovations, indicates a need for more effective approaches in this prevalent disease category.

Declining or Waning

While the journal continues to thrive in many areas, certain themes have shown a decline in prominence over recent years. This may reflect shifting research priorities or advancements in other areas.
  1. Basic Science and Animal Studies:
    There has been a noticeable reduction in the publication of basic science and animal model studies, as the focus shifts towards clinical applications and human studies that directly impact patient care.
  2. Historical and Epidemiological Analyses:
    Research articles examining historical data or long-term epidemiological trends have become less frequent, possibly indicating a move towards more immediate clinical relevance and actionable findings.
  3. Traditional Chemotherapy Studies:
    The emphasis on traditional chemotherapy regimens has waned as newer therapies, particularly immunotherapies and targeted agents, gain traction in clinical practice, reflecting the evolving landscape of cancer treatment.

Similar Journals

ACTA ONCOLOGICA

Exploring the latest breakthroughs in cancer biology.
Publisher: Medical Journal Sweden ABISSN: 0284-186XFrequency: 12 issues/year

ACTA ONCOLOGICA is a prestigious multidisciplinary journal published by Medical Journal Sweden AB, dedicated to advancing cancer research and clinical practice. As a key resource in the field of oncology, the journal aims to publish high-quality articles that cover significant developments in cancer biology, treatment modalities, and innovative imaging techniques. With an ISSN of 0284-186X and an E-ISSN of 1651-226X, ACTA ONCOLOGICA operates in the United Kingdom and is recognized for its substantial impact, currently holding a Q2 ranking in the categories of Hematology, Medicine (miscellaneous), Oncology, and Radiology, Nuclear Medicine and Imaging in 2023. The journal’s commitment to disseminating pivotal research is reflected in its inclusion in Scopus, with rankings placing it in the top half of its fields. Though it does not currently offer Open Access, it remains an essential resource for researchers, healthcare professionals, and students seeking to stay informed on the latest trends and findings in oncology. Established in 1963, the journal continues to be a cornerstone of cancer research well into 2024.

World Journal of Clinical Oncology

Empowering Oncology with Cutting-Edge Insights
Publisher: BAISHIDENG PUBLISHING GROUP INCISSN: 2218-4333Frequency: 12 issues/year

World Journal of Clinical Oncology, published by BAISHIDENG PUBLISHING GROUP INC, stands as a vital resource in the realm of oncology, providing a dedicated platform for the dissemination of cutting-edge research and clinical advancements. With an ISSN of 2218-4333, this journal facilitates a comprehensive exploration of modern oncology challenges and breakthroughs, targeting researchers, healthcare professionals, and students alike. Although it operates under the traditional subscription model, the impactful nature of its content is reflected in its notable ranking of 60 out of 334 in the category of Medicine _ Oncology, placing it in the 82nd percentile among peer publications. Covering significant topics in clinical oncology from 2014 to 2018, the journal has been instrumental in addressing evolving oncology practices and patient care innovations. By publishing high-quality studies, it remains an essential tool for advancing knowledge and fostering collaboration within the global oncology community.

Journal of Thoracic Oncology

Unveiling the Science Behind Thoracic Cancers
Publisher: ELSEVIER SCIENCE INCISSN: 1556-0864Frequency: 12 issues/year

Journal of Thoracic Oncology, published by Elsevier Science Inc, is a premier scholarly outlet dedicated to advancing the field of thoracic oncology. With an impressive impact factor and consistently rated in the Q1 quartile across several pertinent categories such as Medicine, Oncology, and Pulmonary and Respiratory Medicine, this journal stands at the forefront of research dissemination. Covering a broad scope that includes innovative therapeutic approaches, clinical trials, and the molecular underpinnings of thoracic malignancies, the journal serves as a vital resource for researchers, healthcare professionals, and students seeking to enhance their understanding of thoracic cancer and its treatment. With publication dates converging from 2006 to 2024, the Journal of Thoracic Oncology fosters a collaborative scholarly community by providing a platform for high-quality research while ensuring accessibility through traditional publication formats. Positioned in the heart of New York City, this journal not only reflects the cutting-edge advancements in oncology but also plays a pivotal role in shaping the future of thoracic cancer care.

Cancer Management and Research

Advancing oncology through innovative research.
Publisher: DOVE MEDICAL PRESS LTDISSN: 1179-1322Frequency: 1 issue/year

Cancer Management and Research, published by DOVE MEDICAL PRESS LTD, is a leading open-access journal dedicated to advancing the field of oncology. Since its inception in 2009, this journal has established itself as a vital resource for researchers, clinicians, and healthcare professionals focused on cancer treatment and management. With its robust impact factor and impressive Scopus ranking in the 77th percentile of oncology medicine, it provides a prominent platform for sharing high-quality research. The journal covers a wide range of topics within cancer management, including innovative therapeutic strategies, clinical trials, patient care, and health policy, ensuring a comprehensive approach to current challenges in the field. Operating from New Zealand, it invites contributions that can shape the future of oncology and improve patient outcomes globally, making it an essential addition to the libraries of those engaged in cancer research and practice.

Actas Urologicas Espanolas

Pioneering Insights for Urological Excellence
Publisher: ELSEVIER ESPANAISSN: 0210-4806Frequency: 10 issues/year

Actas Urologicas Espanolas is a prestigious journal published by Elsevier España, dedicated to the field of Urology. Established in 1977, this journal has significantly contributed to advancing knowledge and research in urological medicine and surgery, spanning a comprehensive scope that includes clinical studies, surgical techniques, and the latest innovations in the treatment of urological diseases. With an impact factor reflecting its critical role in the academic community, it is ranked Q3 in the Urology category as of 2023, placing it amongst the valuable resources for professionals and researchers. The journal is indexed under Scopus, achieving a commendable rank of #70 out of 120 in the Medicine-Urology category, situating it within the 42nd percentile. As a significant platform for sharing advancements and findings, it encourages submissions that enhance urological care and improve patient outcomes. Although not an Open Access journal, the publication remains vital for those looking to stay updated on the latest developments in urology. For more details, visit their office located at CALLE DE ZURBANO, 76-4TH FLR LEFT, MADRID, 28010, SPAIN.

BREAST

Empowering oncology with innovative insights.
Publisher: CHURCHILL LIVINGSTONEISSN: 0960-9776Frequency: 6 issues/year

BREAST is a leading peer-reviewed journal dedicated to advancing knowledge and practice in the fields of cancer research, oncology, and surgery, published by Churchill Livingstone. With an impressive impact factor and a prestigious Q1 ranking in multiple categories including Cancer Research, Medicine, and Surgery, the journal consistently delivers high-quality content that informs and inspires researchers, clinicians, and educators. Since its transition to Open Access in 2020, BREAST has significantly expanded its reach, providing immediate and unrestricted access to pivotal studies and findings in breast health and disease management. With a history dating back to 1992 and converging to 2024, the journal serves as an essential resource for the latest developments and innovative approaches in the clinical and biomedical aspects of breast care. Scholars and professionals alike can explore a wealth of research aimed at improving patient outcomes and fostering scientific dialogue in this vital area of healthcare.

BMC Urology

Connecting Researchers to Transform Urological Practices
Publisher: BMCISSN: 1471-2490Frequency: 1 issue/year

BMC Urology is a premier open-access journal dedicated to advancing research in the field of urology, reproductive medicine, and miscellaneous aspects of medicine. Published by BMC since 2001 and based in the United Kingdom, this journal provides a platform for researchers, clinicians, and students to disseminate their findings and explore the latest innovations and advancements within these vital fields. With a notable impact factor and categorization in the Q2 quartile for various categories of medicine, BMC Urology stands as a reputable source, ranking 51st out of 120 in Urology and 44th out of 90 in Reproductive Medicine according to Scopus metrics. The journal fosters knowledge sharing through its open-access model, ensuring that research is accessible to all. As it converges from 2001 to 2024, BMC Urology continues to play a crucial role in shaping the landscape of urological research and providing invaluable insights into clinical practices.

Oncology Research and Treatment

Fostering dialogue for a brighter future in oncology.
Publisher: KARGERISSN: 2296-5270Frequency: 10 issues/year

Oncology Research and Treatment, published by KARGER, is a highly regarded academic journal dedicated to advancing the field of oncology through rigorous research and clinical insights. With a history spanning from 1978 to 1997 and continuing from 2013 to 2024, this journal provides a vital platform for researchers and professionals in cancer research, hematology, and related disciplines. Though currently listed in the Q3 tier of 2023 for Cancer Research, Hematology, and Oncology, its growing readership and open access policy enhance its visibility and impact within the scientific community. Based in Switzerland, the journal features diverse access options, reflecting the global importance of oncology research. With a focus on innovative treatments and the latest methodologies, Oncology Research and Treatment plays a crucial role in fostering collaboration and dialogue among researchers, professionals, and students alike, helping to shape the future of cancer care and management.

International Journal of Clinical Oncology

Advancing the Frontiers of Cancer Care
Publisher: SPRINGER JAPAN KKISSN: 1341-9625Frequency: 6 issues/year

International Journal of Clinical Oncology, published by SPRINGER JAPAN KK, is a leading peer-reviewed journal dedicated to advancing research and clinical practices in the fields of oncology, hematology, and surgery. With its impact factor reflecting its significance and reach in the academic community, this journal serves as a solid platform for researchers, professionals, and students to share and disseminate groundbreaking discoveries and methodologies. Notably, it has secured prestigious rankings in the Q1 category in Medicine (miscellaneous) and Surgery, and Q2 in Hematology and Oncology, illustrating its prominent position in the medical literature. The journal's comprehensive scope addresses pivotal clinical issues from 1996 through 2024, further solidifying its relevance in the ever-evolving landscape of cancer research. Despite not offering open access, the depth and quality of research articles ensure that vital information remains accessible to those committed to improving clinical outcomes in oncology. With a focus on innovative treatments and patient care, the International Journal of Clinical Oncology embodies a commitment to fostering excellence in medical research.

European Urology Oncology

Advancing urological oncology through innovative research.
Publisher: ELSEVIERISSN: Frequency: 6 issues/year

European Urology Oncology is a premier academic journal dedicated to advancing the field of urological oncology through innovative research and interdisciplinary collaboration. Published by Elsevier and based in the Netherlands, this journal runs on the principles of providing high-quality, peer-reviewed content that meets the evolving needs of professionals in medicine, surgery, and oncology. With an impressive 2023 categorization in the Q1 quartiles across multiple disciplines including Medicine (Miscellaneous), Oncology, and Urology, the journal demonstrates its pivotal role in disseminating essential findings that enhance clinical practices. The E-ISSN of this journal is 2588-9311, ensuring accessibility to groundbreaking articles that influence treatment methodologies and patient outcomes. Researchers and professionals relying on the latest evidence in urology and oncology will find this journal essential for keeping abreast of cutting-edge developments and clinical insights that shape the future of healthcare.